Using Virtual Reality (VR) Models for Preoperative Planning
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03334344 |
|
Recruitment Status :
Completed
First Posted : November 7, 2017
Last Update Posted : June 6, 2019
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Kidney Cancer Renal Cell Carcinoma | Device: Ceevra Reveal | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 36 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Using Virtual Reality (VR) Models for Preoperative Planning |
| Actual Study Start Date : | October 24, 2017 |
| Actual Primary Completion Date : | February 28, 2019 |
| Actual Study Completion Date : | March 18, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Intervention Arm
Subjects whose surgeon will be viewing VR models in connection with the in addition to the source CT/MR image
|
Device: Ceevra Reveal
VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image. |
|
No Intervention: Control Arm
Subjects whose surgeon will only be viewing CT/MR images in connection with the case
|
- Hilum Dissection Time [ Time Frame: During procedure ]
- Tumor Localization Time [ Time Frame: During procedure ]
- Tumor Resection Time [ Time Frame: During procedure ]
- Reconstruction Time [ Time Frame: During procedure ]
- Total Operative Time [ Time Frame: During procedure ]
- Blood Loss [ Time Frame: Measured at end of procedure ]
- Clamp Time [ Time Frame: Measured at end of procedure ]
- Conversion to Open [ Time Frame: During procedure ]
- Conversion to Radical [ Time Frame: During procedure ]
- Intraoperative Complication [ Time Frame: During procedure ]
- Patient Hospital Stay [ Time Frame: Measured at time of patient discharge, up to 10 days ]
- Positive Margin [ Time Frame: Measured 1-2 weeks after discharge ]
- Post-Op Complication [ Time Frame: Measured up to 6 months after discharge ]
- Readmission [ Time Frame: Measured up to 6 months after discharge ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is undergoing robotic partial nephrectomy being performed by participating surgeon
- Subject is willing to be randomized between intervention and control arms
Exclusion Criteria:
- Cases involving subjects who are minors, pregnant or require an authorized representative for informed consent
- Cases in which the subject has a solitary or horseshoe kidney
- Cases in which the subject has more than two masses in the applicable kidney
- Cases involving a bilateral operation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03334344
| United States, Washington | |
| Swedish Urology Group | |
| Seattle, Washington, United States, 98104 | |
| Swedish Medical Center | |
| Seattle, Washington, United States, 98122 | |
| Study Director: | Russ Yoshinaka, BS, JD | Sponsor GmbH |
| Responsible Party: | Ceevra, Inc. |
| ClinicalTrials.gov Identifier: | NCT03334344 |
| Obsolete Identifiers: | NCT03421418, NCT03534206, NCT03542565, NCT03556943, NCT03666104 |
| Other Study ID Numbers: |
20171006 |
| First Posted: | November 7, 2017 Key Record Dates |
| Last Update Posted: | June 6, 2019 |
| Last Verified: | June 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Product Manufactured in and Exported from the U.S.: | No |
|
Carcinoma, Renal Cell Kidney Neoplasms Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases |

